Herbal medicine composition for treating new coronavirus pneumonia, its preparation method, detection method and its use
A Chinese herbal medicine composition, comprising Chenpi, Cangzhuang, Houboku, Licorice, Kawamidori, Stone Iris, and Ginger, addresses the symptoms of novel coronavirus pneumonia by ensuring high bioavailability and stability, providing a scalable treatment for novel coronavirus pneumonia.
Patent Information
- Application Number
- JP2022567780
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-05-08
- Filing Date
- 2020-11-13
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2040-11-13
AI Technical Summary
There is a need for an effective treatment for novel coronavirus pneumonia, particularly addressing the dampness and cold symptoms associated with the disease, as current treatments are inadequate.
A Chinese herbal medicine composition comprising Chenpi, Cangzhuang, Houboku, Licorice, Kawamidori, Stone Iris, and Ginger, prepared through a method that extracts active ingredients and forms formulations suitable for industrial production, ensuring high bioavailability and stability.
The herbal medicine composition effectively treats novel coronavirus pneumonia with minimal side effects, demonstrating therapeutic efficacy and industrial scalability, while maintaining quality control through detection methods.
Smart Images

Figure 0007594607000003 
Figure 0007594607000004 
Figure 0007594607000005
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS: This disclosure claims priority to a Chinese application entitled "Chinese herbal composition for treating novel coronavirus pneumonia, its preparation method, detection method and use thereof," filed with the China Patent Office on May 8, 2020, which is Patent Document 1, the entire contents of which are incorporated herein by reference. The present disclosure relates to the technical field of traditional Chinese medicine, specifically to a traditional Chinese medicine composition for treating cold and dampness, in particular to a traditional Chinese medicine composition for treating novel coronavirus pneumonia, its preparation method, detection method and use thereof. [Background technology]
[0002] Depending on the nature of the disease, cold epidemics can be divided into "seasonal cold epidemics" and "plague epidemics". Plague epidemics are epidemic and highly contagious external diseases caused by yin, cold, poison, and evil energy. Plague epidemics can be divided into four types: cold plague epidemic (cold epidemic), cold damp epidemic, cold dry damp epidemic, and yin poison epidemic. Among them, cold damp epidemic is relatively common, and its clinical symptoms are chills and fever, sweatless headache, pain in the limb joints, bitter taste in the mouth and slight thirst, thin white tongue coating that is slightly oily, etc. Floating pulse or floating tight pulse is often caused by a mixture of cold evil and impure dampness, and the general treatment principle is "dispersing cold and removing dampness, avoiding impurity and making muddy". The novel coronavirus is a novel strain of coronavirus that has never appeared in the human body before. Common symptoms after humans are infected with coronavirus include respiratory symptoms, fever, cough, shortness of breath and difficulty in breathing. In more severe cases, the infection may lead to pneumonia, severe acute respiratory syndrome or kidney failure, and even death. There is currently no specific treatment for the disease caused by the novel coronavirus. Among the confirmed novel coronavirus patients, many patients have a large and swollen tongue body, teeth marks, thick and oily tongue coating, and even rotten tongue coating, all of which show the characteristics of "dampness". Combined with the clinical symptoms of the 2019 novel coronavirus pneumonia, the current novel coronavirus pneumonia is centered on "dampness" and also has cold or heat. Therefore, it is necessary to provide a Chinese herbal medicine composition for treating cold and dampness, especially for treating novel coronavirus pneumonia. It is with these considerations in mind that the present disclosure is submitted. [Prior art documents] [Patent documents]
[0003] [Patent Document 1] Chinese patent application CN202010384148.5 Summary of the Invention [Problem to be solved by the invention]
[0004] The first objective of the present disclosure is to provide a herbal medicine composition that has significant therapeutic effects in treating cold and dampness, especially novel coronavirus pneumonia.
[0005] The second objective of the present disclosure is to provide a method for preparing a herbal medicine composition which can fully extract the effective ingredients of the herbal medicine composition, has high bioavailability, is simple in preparation, does not require special equipment, and is suitable for industrial production.
[0006] The third objective of the present disclosure is to provide a use of said herbal medicine composition in preparing a medicament for treating cold and dampness, especially for treating new coronavirus pneumonia. [Means for solving the problem]
[0007] In order to achieve the above objectives, the technical solutions adopted in this application are as follows: The herbal medicine composition for treating novel coronavirus pneumonia is prepared using raw materials with a mixing ratio of 250-400 parts by weight of Unchili Peel, 100-200 parts by weight of Atractylodes Root, 100-200 parts by weight of Magnolia officinalis, 200-300 parts by weight of Licorice Root, 200-300 parts by weight of Acorus Major, 200-300 parts by weight of Calamus Root, 250-330 parts by weight of Jujube, and 100-200 parts by weight of ginger.
[0008] In one preferred method, the herbal composition is mainly prepared using raw materials in the following composition ratio: 270-350 parts by weight of Uncaria tsargassum, 130-175 parts by weight of Atractylodes Root, 130-175 parts by weight of Magnolia officinalis, 200-260 parts by weight of Licorice Root, 200-260 parts by weight of Oriental Green, 200-260 parts by weight of Calamus Root, 280-330 parts by weight of Jujube, and 150-180 parts by weight of Ginger.
[0009] Chenpi: It is the dried, mature fruit skin of citrus mandarin orange and its varieties, which are plants of the Rutaceae family. It has a pleasant fragrance, a warm nature, and acts on the meridians of the lungs and spleen. It has the effects of regulating qi and strengthening the spleen, and drying and dampening phlegm. The main components of Chenpi are mainly flavonoid compounds, volatile oils, limonoids, alkaloids, and trace elements (calcium, potassium, magnesium, sodium, lithium, iron, zinc, manganese, etc.).
[0010] In the present disclosure, typical contents of dried orange peel are, but are not limited to, 250 parts by weight, 270 parts by weight, 290 parts by weight, 310 parts by weight, 330 parts by weight, 350 parts by weight, 370 parts by weight, 390 parts by weight or 400 parts by weight. Cangshu Zhuang: The dried rhizome of the Asteraceae plant, Mao Cangshu Zhuang or Beicangshu Zhuang. It is sour, bitter, and / or warm in nature. It acts on the spleen, stomach, and / or liver meridians. It has the effects of drying dampness, strengthening the spleen, removing wind and cold, and brightening eyesight. In clinical practice, it is used to treat dampness and middle burner, stomach and abdominal distension, diarrhea, edema, beriberi, wind and dampness, numbness and pain, wind and cold, night blindness, and dizziness. Experiments have confirmed that Cangshu Zhuang has anti-inflammatory and antibacterial effects. Cangshu Zhuang mainly contains a volatile oil consisting of a series of sesquiterpenes, polyethylene alkynes, and small amounts of phenols and / or organic acids, as well as sesquiterpene lactones, sesquiterpene glycosides, polysaccharides, and small amounts of flavonoids, among which the main active ingredients are sesquiterpenes and polyethylene alkynes.
[0011] In the present disclosure, typical contents of Atractylodes Rhizome are, but not limited to, 100 parts by weight, 110 parts by weight, 120 parts by weight, 130 parts by weight, 140 parts by weight, 150 parts by weight, 160 parts by weight, 170 parts by weight, 180 parts by weight, 190 parts by weight or 200 parts by weight. Magnolia officinalis: The dried bark, root bark and branch bark of Magnoliaceae plant Magnolia officinalis or Magnolia officinalis with concave leaves. It is bitter, pungent and warm in nature. It acts on the meridians of the spleen, stomach, lungs and / or large intestine. It has the effect of expelling phlegm and dryness and clearing stool. In clinical practice, it is used to treat dampness and wounds, stomach and abdominal congestion and vomiting, food stagnation and qi stagnation, abdominal swelling and constipation, and phlegm and cough. Experiments have confirmed that Magnolia officinalis has antiviral, antibacterial, analgesic and anti-inflammatory effects. Magnolia officinalis mainly contains lignans, alkaloids, phenylethanoid glycosides, phenolic glycosides and / or volatile oil components.
[0012] In the present disclosure, the typical content of magnolia is, but is not limited to, 100 parts by weight, 110 parts by weight, 120 parts by weight, 130 parts by weight, 140 parts by weight, 150 parts by weight, 160 parts by weight, 170 parts by weight, 180 parts by weight, 190 parts by weight or 200 parts by weight. Licorice: The dried root and rhizome of the legume liquorice, swollen liquorice or light liquorice. It is a liquorice with a flat root and acts on the meridians of the heart, lungs and spleen and stomach. It has the effects of toning the spleen and strengthening the qi, clearing heat and detoxifying the body, expectorating and coughing, slowing and relieving pain, and harmonizing various medicines. In clinical practice, it is used to treat spleen and stomach weakness, fatigue, palpitations, excessive cough and phlegm, stomach and / or limbs spasms and acute pain, and to relieve drug toxicity and intensity. Experiments have confirmed that liquorice has anti-inflammatory, antibacterial and / or expectorant and coughing effects. The chemical components of liquorice mainly contain triterpenes, flavonoids and liquorice polysaccharides.
[0013] In the present disclosure, typical amounts of licorice include, but are not limited to, 200 parts by weight, 210 parts by weight, 220 parts by weight, 230 parts by weight, 240 parts by weight, 250 parts by weight, 260 parts by weight, 270 parts by weight, 280 parts by weight, 290 parts by weight, or 300 parts by weight. Patchouli: The dried above-ground part of the patchouli plant of the Lamiaceae family. It has a sour taste and a slightly warm nature. It acts on the spleen, stomach and / or lung meridians. It has the effects of aromatizing turbidity, stopping vomiting and releasing heat. In clinical practice, it is used to treat damp and turbidity, stomach and abdominal congestion and vomiting, hot and damp appearance syndrome, damp and hot initial onset, fever and fatigue, chest cramps, cold and damp heat, abdominal pain and vomiting, and nasal headache. Experiments have confirmed that patchouli has antiviral, antibacterial, analgesic and anti-inflammatory properties. The main active ingredients of patchouli are patchouli alcohol and pogostone.
[0014] In the present disclosure, typical amounts of Kawamidori include, but are not limited to, 200 parts by weight, 210 parts by weight, 220 parts by weight, 230 parts by weight, 240 parts by weight, 250 parts by weight, 260 parts by weight, 270 parts by weight, 280 parts by weight, 290 parts by weight, or 300 parts by weight. Acorus gramineus: It is the dried rhizome of Acorus gramineus, a plant of the Araceae family. It is sour, bitter and warm in nature. It acts on the meridians of the heart and stomach. It has the effects of opening the orifices and phlegm, awakening the soul and promoting wisdom, and transforming dampness into an open stomach. In clinical practice, it is used to treat epilepsy, amnesia, insomnia, tinnitus and hearing loss, stomach upset and hunger, and open-mouthed diarrhea. Experiments have confirmed that Acorus gramineus contains various spasmolytic and asthmatic components, and its decoction can promote the secretion of digestive juices and relieve spasms of intestinal smooth muscles. In modern pharmacological research, its chemical components are mainly divided into volatile and non-volatile components. At present, there are many studies on the volatile part, but few on the non-volatile part. The volatile components are relatively complex with over 60 known compounds, the main structural types being phenylpropanoids (simple forms of phenylpropanoids, lignans and coumarins) and terpene (mono-, sesqui-, di- and triterpene) compounds. The non-volatile components are mainly alkaloids, aldehydes and acids, quinones and ketones, sterols, amino acids and sugars.
[0015] In the present disclosure, a typical content of Araceae is, but is not limited to, 200 parts by weight, 210 parts by weight, 220 parts by weight, 230 parts by weight, 240 parts by weight, 250 parts by weight, 260 parts by weight, 270 parts by weight, 280 parts by weight, 290 parts by weight or 300 parts by weight. Jujube: The dried, mature fruit of the jujube plant, which belongs to the Rhamnaceae family. It is sweet and warm in nature. It acts on the spleen, stomach and / or heart meridians. It has the effects of toning the central qi and nourishing blood and easing the spirit. In clinical practice, it is used to treat spleen deficiency, poor diet, poor bowel movement and gynaecological disorders. Experiments have confirmed that jujube has neurosuppressant, hepatoprotective, muscle strengthening, anticancer, antimutagenic and antilipid peroxidation effects. The main components of the volatile oil in jujube are dimethyl phthalate, ethyl tridecanoate, diisobutyl phthalate, 3-hydroxy-2-butanone, furfurylalcohol, 2-cyclopentene-1,4-dione, palmitic acid ethyl ester, and / or methyl linolenate.
[0016] In the present disclosure, the typical content of jujube is, but is not limited to, 250 parts by weight, 260 parts by weight, 270 parts by weight, 280 parts by weight, 290 parts by weight, 300 parts by weight, 310 parts by weight, 320 parts by weight or 330 parts by weight. Ginger: It is the fresh rhizome of the plant of the Zingiberaceae family. It is sour and slightly warm in nature. It acts on the meridians of the lungs, spleen and / or stomach. It has the effects of relieving cold, warming and stopping vomiting, making phlegm and coughing, and detoxifying fish and crab. It is used to treat cold and wind, cold and vomiting, cold and phlegm and coughing, and fish and crab poisoning. Experiments have confirmed that ginger has nerve suppressing, hepatoprotective, muscle strengthening, anti-cancer, anti-mutation, and anti-lipid peroxidation effects. According to modern research, the main components of ginger are volatile oils, 6-gingerol and diphenylheptane.
[0017] In the present disclosure, a typical content of ginger is, but is not limited to, 100 parts by weight, 110 parts by weight, 120 parts by weight, 130 parts by weight, 140 parts by weight, 150 parts by weight, 160 parts by weight, 170 parts by weight, 180 parts by weight, 190 parts by weight or 200 parts by weight.
[0018] In one preferred method, the herbal medicine composition of the present disclosure is prepared with raw materials in the following composition ratios by weight: 340.9 parts by weight of Unchili Peel, 170.5 parts by weight of Atractylodes Rhizome, 170.5 parts by weight of Magnolia officinalis, 255.7 parts by weight of Licorice Root, 255.7 parts by weight of Oriental Calamus, 255.7 parts by weight of Jujube, 318.2 parts by weight of Jujube, and 163.6 parts by weight of Ginger.
[0019] In one embodiment, the herbal composition of the present disclosure further comprises a certain weight part of auxiliary material, preferably 500-700 weight parts of auxiliary material, and preferably, the auxiliary material is a filler.
[0020] More preferably, the filler is dextrin, soluble starch or lactose.
[0021] The herbal medicine compositions of the present disclosure can be prepared into various formulations, including but not limited to oral liquids, granules, powders, dripping pills, capsules, effervescent agents or tablets, by conventional techniques in the art.
[0022] In one embodiment, the method for preparing the herbal medicine composition of the present disclosure includes: The method includes the steps of adding water to the raw materials in the weight ratio to wet them, boiling them to extract them, filtering them to obtain an extract, concentrating them under reduced pressure, spray-drying them to obtain a spray powder, adding and mixing an adhesive, and preparing granules by a wet method.
[0023] In one specific embodiment, the method for preparing the herbal medicine composition of the present disclosure includes: Step (1) of weighing out each raw material component in proportions by weight; (2) adding 15 parts by weight of water, infusing for 0.5 hours, and then boiling and extracting twice for 0.5 hours each time, combining the boiled liquids, and filtering to obtain an extract; Step (3) of concentrating the extract from step (2) under reduced pressure at 70°C to obtain a concentrated solution having a relative density measured at 50°C of 1.10 to 1.20 g / mL; (4) taking the concentrated solution of step (3) and spray drying it to obtain a spray powder; and and step (5) of taking the spray powder of step (4), adding and mixing dextrin, and preparing granules by a wet method. In a preferred embodiment, the spray drying conditions in step (4) are: inlet temperature 125° C., pressure 102.5 MPa, blow rate 80%, and flow rate 20-30 / s.
[0024] In another embodiment, the method for preparing the herbal medicine composition of the present disclosure includes: extracting the raw material of the weight ratio by steam distillation and collecting the volatile oil; filtering the residue from the decoction to obtain an extract, concentrating the extract under reduced pressure, and spray-drying it to obtain a spray powder; adding anhydrous ethanol solution to the volatile oil and incorporating an aqueous β-cyclodextrin solution to prepare a cyclodextrin clathrate; and adding and mixing the spray powder and the volatile oil clathrate with an adhesive to prepare granules by a wet method.
[0025] In one preferred embodiment, in the method for preparing the herbal composition disclosed herein, extraction is carried out 2-3 times by steam distillation, and the extracts obtained each time are combined and used in the next step.
[0026] In one preferred embodiment, in the preparation method of the herbal medicine composition disclosed herein, volatile oils are extracted by adding 8-15 times water in steam distillation.
[0027] In one preferred embodiment, in the β-cyclodextrin aqueous solution, the weight of β-cyclodextrin is 8-12 times the weight of the volatile oil, and the weight of water is 10-20 times the weight of the β-cyclodextrin, preferably the weight of β-cyclodextrin is 10 times the weight of the volatile oil, and the weight of water is 15 times the weight of the β-cyclodextrin.
[0028] In another specific embodiment, the method for preparing the herbal medicine composition of the present disclosure includes: (a) weighing out each raw material component by weight and grinding it into a coarse powder; (b) adding 8-15 parts by weight of water, infusing for 0.5 hours, followed by extraction by steam distillation, collecting the volatile oil, and filtering the residue from the decoction to obtain an extract; (c) collecting the extract obtained in step (b) and concentrating it under reduced pressure until the relative density measured at 60°C is 1.10-1.20 g / mL to obtain a concentrated solution; (d) spray drying the concentrate of step (c) to obtain a spray powder; (e) adding anhydrous ethanol solution to the volatile oil collected in step (b), clathrating the β-cyclodextrin aqueous solution with stirring for 3 hours, refrigerating, filtering, and drying the filtrate to obtain a volatile oil clathrate; and and step (f) of adding and mixing dextrin to the spray powder of step (d) and the volatile oil clathrate of step (e) to prepare granules by a wet method.
[0029] In one preferred method, in step (b), the residue is added with 8 to 15 times the amount of water, and then extracted by steam distillation for 1 hour. The decoction is filtered to obtain an extract, and the extracts obtained in the two steps are combined and used in the next step.
[0030] In a preferred method, in step (b), the concentration is carried out under reduced pressure at 70°C, and in step (c), the spray drying conditions are: air inlet temperature 160-180°C, air outlet temperature 80-90°C.
[0031] In one preferred method, in step (e), the weight of β-cyclodextrin in the β-cyclodextrin aqueous solution is 8-12 times the weight of the volatile oil, and the weight of water is 10-20 times the weight of the β-cyclodextrin, preferably the weight of β-cyclodextrin is 10 times the weight of the volatile oil, and the weight of water is 15 times the weight of the β-cyclodextrin.
[0032] In one embodiment, the present disclosure provides a method for detecting the quality of the herbal medicine composition, which includes hesperidin thin layer chromatography qualitative identification and hesperidin content measurement, and preferably further includes thin layer chromatography qualitative identification of 6-gingerol, licorice and / or magnolol.
[0033] In one embodiment, the thin layer chromatography qualitative identification includes: 2g of the granule powder prepared by the herbal composition is taken, 25ml of water is added to dissolve, and 20ml of ethyl acetate is added for each extraction by shaking twice, the extracts are combined, evaporated to dryness, and the residue is dissolved in 1ml of methanol, which is used as the test solution; separately, hesperidin control is taken, and methanol is added to prepare a saturated solution, which is used as the control solution; according to the thin layer chromatography test method, 2-5μL of the test solution and 5μL of the control solution are respectively sucked up on the same silica gel G thin layer plate, and developed with ethyl acetate-methanol-water in a volume ratio of 20:3:2 as the developing solvent, and taken out and dried, sprayed with 5% aluminum trichloride ethanol solution, heated at 105℃ for 5-10 minutes, and inspected under ultraviolet lamp 365nm, and the same color spots appear in the chromatography of the test sample at the positions corresponding to the chromatography of the control medicinal material; (1);
[0034] Step (1) is used as the test sample solution, and 6-gingerol is taken as the control sample, and ethyl acetate is added to prepare a solution containing 1 mg per mL, which is used as the control sample solution. According to the thin layer chromatography test method, 3-10 μL of the test sample solution and 1 μL of the control sample solution are absorbed and spotted on the same silica gel G thin layer plate, respectively, and developed with a volume ratio of 2:1:1 petroleum ether (60-90°C)-trichloromethane-ethyl acetate as the developing solvent, and then taken out and dried, and sprayed with 2% vanillin sulfuric acid solution, and heated at 105°C until spots are clearly visible, and the same color spots appear in the chromatography of the test sample at the positions corresponding to the chromatography of the control sample; Step (2);
[0035] Take 3 g of the granules prepared in the above-mentioned herbal medicine composition, add 40 ml of water to dissolve, shake and extract 3 times with n-butanol, 20 ml each time, combine the n-butanol solution, evaporate and dry 20 ml each time, add 1 ml of methanol to the residue to dissolve, and use it as the test sample solution; separately, take 1 g of licorice control medicinal material, add 40 ml of water, reflux for 1 hour, cool, filter, shake and extract 3 times with n-butanol, 20 ml each time, combine the n-butanol solution, evaporate and dry 20 ml each time, add 1 ml of methanol to the residue to dissolve, and use it as the test sample solution. Add and dissolve, and use as control solution; According to thin layer chromatography test method, 2-5μL of the test solution and 5μL of the control drug solution are absorbed, spotted on silica gel G thin layer plate respectively, and developed with ethyl acetate-formic acid-glacial acetic acid-water of volume ratio 15:1:1:2 as developing solvent, taken out and dried, sprayed with 10% sulfuric acid-ethanol solution, heated at 105℃ until spots are clearly visible, and inspected with ultraviolet lamp 365nm, and the same color fluorescent main spots appear in the position corresponding to the chromatography of the control drug in the chromatography of the test sample; and
[0036] (4) taking 6g of the granules prepared by the herbal composition, grinding finely, adding 40ml of ethyl acetate, ultrasonicating for 30 minutes, filtering, evaporating the filtrate to dryness, adding 1ml of methanol to the residue to dissolve it, and using it as the test solution; taking magnolol separately, adding methanol to prepare a mixed solution containing 1mg per ml, and using it as the control solution; according to the thin layer chromatography test method, taking 10-15μL of the test solution and 5μL of the control solution, spotting them on the same silica gel G thin layer plate respectively, developing with toluene-ethyl acetate-methanol in a volume ratio of 18:3:1 as the developing solvent, taking out and drying, spraying with 1% vanillin sulfuric acid solution, and heating at 105℃ until spots are clearly visible, and the same color spots appear in the chromatography of the test sample at the positions corresponding to the chromatography of the control sample.
[0037] In one specific embodiment, the hesperidin content is measured by high performance liquid chromatography, specifically: Octadecyl silane chemically bonded silica gel (ODS) is used as a packing material. A volume ratio of acetonitrile: 0.1% phosphoric acid solution = 19:81 was used as the mobile phase. The detection wavelength was 283 nm, and the flow rate was 1.0 ml / min. The theoretical plate number calculated based on the hesperidin peak is greater than or equal to 2000; Take an appropriate amount of hesperidin control, weigh it accurately, and add methanol to prepare a solution containing 15 μg per mL to prepare a control solution. Take the herbal medicine composition of the present application, finely grind it, sieve it through a No. 5 sieve, take 0.3 g, weigh it precisely, put it into a stoppered Erlenmeyer flask, add 50 ml of 10% methanol precisely, weigh it, sonicate it for 30 minutes, cool it down, weigh it again, make up the weight lost by the methanol, shake it well, filter it, and take the filtrate to prepare the test sample solution; The measurement method is to precisely suck up 10 μL of the control solution and the test solution, inject them into a liquid chromatograph, and measure them. Each gram of granules in this composition contains hesperidin (C 28 H 34 O 15 ) contains greater than or equal to 2.325 mg of dermis.
[0038] The present disclosure ensures the stability and quality control of granule quality by measuring the content of hesperidin in a herbal medicine composition granule, while at the same time ensuring the content of effective ingredients in the herbal medicine composition through measuring the hesperidin content and transfer rate, since the physicochemical properties of hesperidin are stable, thereby enabling more effective control of product quality.
[0039] The present disclosure provides a use of the herbal composition in preparing a medicament for treating cold and dampness, and optionally a use of the herbal composition in preparing a medicament for treating novel coronavirus pneumonia. Effect of the Invention
[0040] The beneficial effects of the present application are as follows: The herbal medicine preparation provided in the present disclosure is composed of a certain weight ratio of Unchili Peel, Atractylodes Macrocephala, Magnolia Officinalis, Licorice Root, Wildflower, Calamus, Jujube, and Ginger. The active ingredients of these several medicines complement and cooperate with each other. The herbal medicine preparation obtained through the combination of each raw drug has few side effects and can treat cold and dampness, especially for treating new coronavirus pneumonia, and has remarkable therapeutic effects.
[0041] The preparation method disclosed herein can fully extract the effective components of the herbal medicine preparation, has high bioavailability, is simple in preparation, does not require special equipment, and is suitable for industrial production. The preparation method disclosed herein can improve both the hesperidin content and the transfer rate of hesperidin in the herbal medicine composition.
[0042] The detection method of the present disclosure can effectively control the quality of the herbal medicine composition, and has good stability and reproducibility.
[0043] Most of the herbal medicine ingredients of the present application contain volatile oil components, and the comprehensive method of steam distillation extraction and volatile oil encapsulation reduces the loss of volatile oil, shortens the process time, and improves the utilization rate of volatile oil in the finished herbal medicine preparation, thereby better exerting the medicinal efficacy of the herbal medicine composition. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the preferred embodiment of the present invention will be described in detail with reference to the accompanying drawings. [Brief description of the drawings]
[0044] [Figure 1] This is a thin-layer chromatogram for the qualitative identification of hesperidin by thin-layer chromatography in Example 6 of the present disclosure, in which the first column on the left is the control solution, and the three columns on the right are the test solution of the herbal medicine granules of the present disclosure. [Diagram 2] This is a thin-layer chromatogram for qualitative identification of 6-gingerol by thin-layer chromatography in Example 6 of the present disclosure, where the first column on the left is the control solution, and the three columns on the right are the test solution of the herbal medicine granules of the present disclosure. [Diagram 3] This is a thin-layer chromatogram for qualitative identification of licorice by thin-layer chromatography in Example 6 of the present disclosure, where the first column on the left is the control solution, and the three columns on the right are the test solution of the herbal medicine granules of the present disclosure. [Figure 4] This is a thin-layer chromatogram for qualitative identification of magnolol by thin-layer chromatography in Example 6 of the present disclosure, where the first column on the left is the control solution, and the three columns on the right are test solution of the herbal medicine granules of the present disclosure. [Diagram 5] 1 is a high performance liquid chromatogram of a test sample of the herbal medicine granules of the present disclosure in measuring the hesperidin content in Example 7 of the present disclosure. [Figure 6] 1 is a high performance liquid chromatogram of a control sample in measuring hesperidin content in Example 7 of the present disclosure. [Figure 7]The herbal extract of the present disclosure exhibited an inhibitory effect on COVID-19 pseudovirus-infected HEK293-ACE2 cells, with Student's t-test, ***P<0.001, **P<0.01 compared with the negative control group. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] The implementation methods of the present disclosure will be specifically described below in conjunction with examples. Those skilled in the art can understand that the following examples are only used to illustrate the present disclosure and should not be considered as limiting the scope of the present disclosure. If no specific conditions are specified in the examples, they are carried out according to conventional conditions or conditions suggested by the manufacturer. The reagents or equipment used without the manufacturer's name are all conventional products available on the market.
[0046] The herbal medicine composition of the present invention will be described in more detail below in combination with Examples 1-7 and Comparative Examples 1-3.
[0047] Example 1 In preparing the disclosed herbal composition, the raw materials are weighed out in the following weight parts: 7.5g of Uncaria tsargassum, 3.75g of Atractylodes macrocarpa, 3.75g of Magnolia officinalis, 5.625g of Licorice Root, 5.625g of Acorus gramineus, 5.625g of Calamus sieboldii, 3.5g of Jujube, and 1.8g of Ginger. Each raw material is weighed out in the weight parts, and an appropriate amount of water is added, decoction is made over low heat, and the decoction is boiled down to 400mL to prepare the decoction.
[0048] Example 2 In the preparation of the disclosed herbal medicine composition, the raw materials are weighed in the following weight parts: 250g of Chenpi, 100g of Atractylodes Root, 100g of Magnolia Root, 200g of Licorice Root, 200g of Atractylodes Root, 200g of Acorus Major, 250g of Jujube and 100g of Ginger. Each raw material is weighed in the proportion of weight parts, and 15 times the weight parts of water is added. After infiltration for 0.5 hours, it is boiled twice for 0.5 hours each time to extract, and the boiled liquid is combined and filtered to obtain an extract. The extract is concentrated under reduced pressure at 70°C to obtain a concentrate with a relative density of 1.10-1.20g / mL measured at 50°C. The concentrate is spray-dried to obtain a spray powder. The spray powder is taken, and an appropriate amount of dextrin is added and mixed to prepare granules by wet method.
[0049] Example 3 In the preparation of the disclosed herbal medicine composition, the raw materials are weighed in the following weight parts: 400g of Chenpi, 200g of Atractylodes Root, 200g of Magnolia officinalis, 300g of Licorice Root, 300g of Atractylodes Root, 300g of Acorus Major, 330g of Jujube and 200g of Ginger. Each raw material is weighed in the proportion of weight parts, and 15 times the weight parts of water is added. After infiltration for 0.5 hours, it is boiled twice for 0.5 hours each time and extracted. The boiled liquid is combined and filtered to obtain an extract. The extract is concentrated under reduced pressure at 70°C to obtain a concentrate with a relative density of 1.10-1.20g / mL measured at 50°C. The concentrate is spray-dried to obtain a spray powder. The spray powder is taken, dextrin is added and mixed, and granules are prepared by wet method.
[0050] Example 4 In the preparation of the disclosed herbal medicine composition, the raw materials are weighed in the following weight parts: 375g of Chenpi, 187.5g of Atractylodes Root, 187.5g of Magnolia officinalis, 281.3g of Licorice Root, 281.3g of Atractylodes Root, 281.3g of Acorus Root, 330g of Jujube and 180g of Ginger. Each raw material is weighed in the proportion of weight parts, and 15 times the weight parts of water is added, soaked for 0.5 hours, then boiled twice for 0.5 hours each time for extraction, and the boiled liquid is combined and filtered to obtain an extract. The extract is concentrated under reduced pressure at 70°C to obtain a concentrate with a relative density of 1.10-1.20g / mL measured at 50°C. The concentrate is spray-dried to obtain a spray powder. The spray powder is taken, dextrin is added and mixed, and granules are prepared by wet method.
[0051] Example 5 In the preparation of the disclosed herbal medicine composition, the raw materials are weighed in the following weight parts: 340.9g of Chenpi, 170.5g of Atractylodes Root, 170.5g of Magnolia Root, 255.7g of Licorice Root, 255.7g of Acanthus Root, 255.7g of Acorus Root, 318.2g of Jujube, and 163.6g of Ginger. Each raw material is weighed in the weight parts and crushed into coarse powder. 15 times the weight parts of water are added, and after infiltration for 0.5 hours, the mixture is extracted by steam distillation for 4 hours while collecting volatile oil. The residue is filtered from the decoction to obtain an extract, which is prepared, and 15 times the weight parts of water are added to the residue, and the mixture is extracted by steam distillation for 1 hour, and the decoction is removed, which is prepared, and the extract is combined and filtered. The obtained extract is concentrated under reduced pressure to obtain a concentrate having a relative density of 1.10-1.20g / mL measured at 60℃. The concentrate is spray-dried to obtain spray powder. Anhydrous ethanol solution is added to the collected volatile oil, and β-cyclodextrin aqueous solution is used to encapsulate with stirring for 3 hours, refrigerated, filtered, and the filtrate is dried to obtain volatile oil clathrate. Dextrin is added to the spray powder and volatile oil clathrate, and mixed to prepare granules by wet method.
[0052] Example 6 Thin-layer chromatography was used to identify the herbal medicine composition granules prepared in Example 4. The details are as follows:
[0053] 2 g of the granule powder prepared in the above-mentioned herbal composition is dissolved by adding 25 ml of water, and is extracted twice by shaking with ethyl acetate, 20 ml each time. The extracts are combined and evaporated to dryness. The residue is dissolved in 1 ml of methanol, which is used as the test sample solution. Separately, a hesperidin control sample is taken and saturated with methanol, which is used as the control sample solution. According to the thin layer chromatography test method, 2-5 μL of the test sample solution and 5 μL of the control sample solution are respectively sucked up on the same silica gel G thin layer plate, and developed with ethyl acetate-methanol-water in a volume ratio of 20:3:2 as the developing solvent. The plate is taken out and dried, sprayed with 5% aluminum trichloride ethanol solution, heated at 105°C for 5-10 minutes, and inspected under an ultraviolet lamp at 365 nm. The same color spots appear in the chromatography of the test sample at the positions corresponding to those of the chromatography of the control drug. (1)
[0054] The test sample solution in step (1) is used as the test sample, and 6-gingerol is taken as the control sample, and ethyl acetate is added to prepare a solution containing 1 mg per mL, which is used as the control sample solution. According to the thin layer chromatography test method, 3-10 μL of the test sample solution and 1 μL of the control sample solution are absorbed and spotted on the same silica gel G thin layer plate, respectively, and developed with petroleum ether (60-90°C)-trichloromethane-ethyl acetate in a volume ratio of 2:1:1 as the developing solvent, and then removed and dried, and sprayed with 2% vanillin sulfuric acid solution, and heated at 105°C until spots are clearly visible, and the same color spots appear in the chromatography of the test sample at the positions corresponding to the chromatography of the control sample. Step (2).
[0055] Take 3 g of the granules prepared in the above-mentioned herbal medicine composition, add 40 ml of water to dissolve, shake and extract 3 times with n-butanol, 20 ml each time, combine the n-butanol solution, evaporate and dry 20 ml each time, add 1 ml of methanol to the residue to dissolve, and use as the test sample solution; separately, take 1 g of licorice control medicinal material, add 40 ml of water, reflux for 1 hour, cool, filter, shake and extract 3 times with n-butanol, 20 ml each time, combine the n-butanol solution, evaporate and dry 20 ml each time, add 1 ml of methanol to the residue to dissolve, and use as the test sample solution; and dissolve it, which is used as the control solution. According to the thin layer chromatography test method, 2-5μL of the test sample solution and 5μL of the control drug solution are absorbed and spotted on a silica gel G thin layer plate respectively, and developed with ethyl acetate-formic acid-glacial acetic acid-water in a volume ratio of 15:1:1:2 as the developing solvent, taken out and dried, sprayed with 10% sulfuric acid-ethanol solution, heated at 105℃ until the spots are clearly visible, and inspected under an ultraviolet lamp at 365nm. The chromatography of the test sample shows the same color main fluorescent spots at the positions corresponding to the chromatography of the control drug. Step (3).
[0056] Take 6g of the granules prepared by the above-mentioned herbal composition, finely grind them, add 40ml of ethyl acetate, ultrasonicate for 30 minutes, filter, evaporate the filtrate to dryness, add methanol to the residue to dissolve, and use it as the test solution; take magnolol separately, add methanol to prepare a mixed solution containing 1mg per mL, and use it as the control solution; according to the thin layer chromatography test method, take 10-15μL of the test solution and 5μL of the control solution, spot them on the same silica gel G thin layer plate respectively, develop them with toluene-ethyl acetate-methanol in a volume ratio of 18:3:1 as the developing solvent, take them out and dry them, spray them with 1% vanillin sulfuric acid solution, and heat them at 105℃ until spots are clearly visible, and in the chromatography of the test sample, spots of the same color appear at the position corresponding to the chromatography of the control sample. (4) Thin layer chromatograms of the test and control products are shown in Figures 1-4.
[0057] Example 7 The content of the herbal composition granules prepared in Example 4 is measured by high performance liquid chromatography. Chromatography conditions and system applicability test: Octadecyl silane chemically bonded silica gel (ODS) is used as the packing material, acetonitrile: 0.1% phosphoric acid solution = 19:81 volume ratio is used as the mobile phase, and the detection wavelength is 283 nm. The number of theoretical plates calculated based on the hesperidin peak is greater than or equal to 2000.
[0058] Preparation of control solution: Take hesperidin control, weigh it accurately, and add methanol to prepare a solution containing 50 μg per mL.
[0059] Preparation of test sample solution: take the granules prepared in Example 4, mix evenly, and grind finely. Take 0.3g, weigh accurately, and put into a stoppered Erlenmeyer flask. Add 50ml of methanol accurately, pack tightly, weigh, and ultrasonicate for 30 minutes (power 500W, frequency 40kHz), then cool and weigh again, make up for the weight lost with methanol, shake well, and filter, and obtain the filtrate.
[0060] Measurement method: Accurately take 10 μL of the control solution and test solution, inject them into the liquid chromatography, and measure.
[0061] In measuring the hesperidin content, the high performance liquid chromatogram of the test sample of the herbal medicine granules of the present disclosure is shown in FIG. 5, and the high performance liquid chromatogram of the control sample is shown in FIG.
[0062] Comparative Example 1 In the preparation of the herbal composition, the raw materials are weighed out in the following weight parts: 375g of Chenpi, 187.5g of Atractylodes macrocarpa, 187.5g of Magnolia officinalis, 281.3g of Licorice Root, 281.3g of Atractylodes japonica, and 281.3g of Acorus gramineus. Each raw material is weighed out in the proportion of weight parts, and 15 times the weight parts of water are added. After infiltration for 0.5 hours, the raw materials are boiled twice for 0.5 hours each time to extract. The boiled liquid is combined and filtered to obtain an extract. The extract is concentrated under reduced pressure at 70℃ to obtain a concentrate with a relative density of 1.10-1.20g / mL measured at 50℃. The concentrate is spray-dried to obtain a spray powder. The spray powder is taken, dextrin is added and mixed, and granules are prepared by wet method.
[0063] Comparative Example 2 The content of the herbal composition granules prepared in Comparative Example 1 was measured by high performance liquid chromatography. Chromatography conditions and system applicability test: Octadecyl silane chemically bonded silica gel (ODS) is used as the packing material, acetonitrile: 0.1% phosphoric acid solution = 19:81 volume ratio is used as the mobile phase, and the detection wavelength is 283 nm. The number of theoretical plates calculated based on the hesperidin peak is greater than or equal to 2000. Preparation of control solution: Take hesperidin control, weigh it accurately, and add methanol to prepare a solution containing 50 μg per mL. Preparation of test sample solution: Take the granules prepared in Comparative Example 1, mix uniformly, and grind finely. Take 0.3 g, weigh accurately, and put into a stoppered Erlenmeyer flask. Add 50 ml of methanol accurately, pack tightly, weigh, and ultrasonicate for 30 minutes (power 500 W, frequency 40 kHz), then cool and weigh again, make up for the weight lost by methanol, shake well, and filter, and obtain the filtrate. Measurement method: Accurately take 10 μL of the control solution and test solution, inject them into the liquid chromatography, and measure.
[0064] Comparative Example 3 The raw ingredients are weighed out as follows: 7.5g of Chenpi, 3.75g of Atractylodes macrocarpa, 3.75g of Magnolia officinalis, 5.625g of Licorice Root, 5.625g of Kawamidori, 5.625g of Acorus gramineus, 1 jujube, and 3 slices of ginger. Separately from the six medicines mentioned above, the jujube and ginger are boiled to prepare a decoction.
[0065] [Table 1]
[0066] The results showed that the content and transfer rate of the effective ingredient hesperidin in Example 7 were significantly higher than those in Comparative Example 2, which is believed to be because the jujube or ginger ingredients increase the stability of hesperidin in water.
[0067] Administration drug toxicity test In this study, all content and procedures related to animal testing complied with the laws and regulations regarding the use and care of laboratory animals and the relevant regulations of the Institutional Animal Care and Use Committee (IACUC) of this institution.
[0068] Materials and Methods: In this study, 40 healthy SD rats were randomly divided into 4 groups: a solvent control group, a low-dose, a medium-dose and a high-dose group of the herbal composition of the present application, with 10 rats per group, half male and half female. The rats in each group were orally administered with a solvent control (pure water) or different concentrations of the herbal composition of the present application at a dose of 20mL / kg / time, 3 times at intervals of at least 4 hours each time. Here, the doses of the low-dose, medium-dose and high-dose groups of the herbal composition of the present application were 3, 9 and 37.5g extract / kg, respectively. After administration, the rats were continuously observed for 14 days, and the day of the first administration was set as the first day of the study. During the study period, the general condition of the SD rats in each group was observed every day, and the body weight was measured on the first, fourth, eighth and fourteenth days of the study, and the food intake was measured on the second, fifth, eighth and twelfth days of the study. On the fifteenth day of the study, the rats in each group were euthanized as scheduled, and gross anatomical observations were performed.
[0069] Results: (1) General condition: On the first day of the test, all female and male rats in the high-dose group showed symptoms of loose stools, and the color of urine was abnormal and light green. From the second day of the test, the above symptoms disappeared, and there were no obvious abnormalities in the general symptoms, behavioral activity, respiratory state, five senses, body surface, feces and genitals of the rats in each group, and no animals died during the test. (2) Body weight and food intake: There were no abnormal changes in the body weight and food intake of the rats in each group during the test. (3) Macroscopic anatomical observation: On the 15th day of the test, macroscopic anatomical observation was performed, and there were no obvious abnormal changes in the color, shape, size and texture of the major organs or tissues such as the heart, liver, spleen, lungs, kidneys and thymus of the rats in each group.
[0070] Conclusion: Under the conditions of this study, when SD rats were orally administered 3, 9, and 37.5 g extract / kg of the disclosed herbal medicine composition each time, the maximum tolerated dose (MTD) was 37.5 g extract / kg, equivalent to 168.5 g herbal medicine / kg.
[0071] Clinical Trials The herbal composition prepared in Example 1 was used to conduct clinical trials. (1) Subjects: Patients aged 13-54 years old who were infected with novel coronavirus pneumonia (nucleic acid test positive) at Danjiangkou City Traditional Chinese Medicine Hospital. These patients had fever (body temperature ≥ 38°C) and cough, decreased total white blood cell count and lymphocyte count in general blood tests, and ground-glass opacities of different degrees in the lungs. (2) Treatment method: Take twice a day, once in the morning and once in the evening, 200 mL each time, for three days. (3) The diagnostic criteria for cure or palliative care are as follows: 1. White blood cells and lymphocytes return to normal. 2. The ground-glass opacities in the patient's lungs are absorbed and disappear. 3. Real-time fluorescent RT-PCR detection of novel coronavirus nucleic acid converts to negative. 4. No other organic disorders.
[0072] Typical clinical cases 1. Ms. Guo, basic information of the patient: 29-year-old female, the patient has a history of working in a corona-affected area. Symptoms: fever, cough, sputum, fatigue, loss of appetite. Imaging examination: left lower lobe, right middle lobe, left upper lobe lingual side and right lower lobe infected. Pathogen examination: novel coronavirus nucleic acid test positive. After treatment with the disclosed herbal medicine, fever disappeared, cough and sputum were relieved, fatigue and loss of appetite were improved. Pulmonary inflammation was absorbed. Novel coronavirus nucleic acid test was negative, and no other side effects were observed during the period. 2. Mr. Shen, patient basic information: 25-year-old male. Symptoms: fever, body pain, loss of appetite and fatigue. Imaging examination: right lower lobe infection. Pathogen examination: novel coronavirus nucleic acid test positive. After treatment with the disclosed herbal medicine, fever disappeared, body pain disappeared, fatigue and loss of appetite improved. Lung inflammation was absorbed. Novel coronavirus nucleic acid test negative, and no other side effects were observed during the period.
[0073] In vitro drug effect experiment of the disclosed herbal medicine composition: The inhibitory effect of the disclosed herbal medicine composition on the cell line HEK293 stably expressing ACE2 receptor infected with COVID-19 pseudovirus was investigated. 1. Preparation of test articles and dosing formulations: Test item: 16g of the yellow-brown powder of the herbal medicine composition extract of the present disclosure (extract of Example 4). Hesperidin content: 13.12mg / g. Source: Beijing Handi Pharmaceutical Co., Ltd. Preparation of dosage formulation: Weigh out 20 mg of the herbal extract powder, add it to 1 mL of DMSO, and mix evenly to obtain a mother solution of 20 mg / mL. Take 100 μL of the mother liquor and add it to 3900 μL of DMEM medium to prepare a solution with a concentration of 5 mg / mL. Take 400 μL of the 0.5 mg / mL solution and add it to 600 μL of DMEM medium to prepare a solution with a concentration of 0.2 mg / mL. Take 500 μL of the 0.2 mg / mL solution and add it to 500 μL of DMEM medium to prepare a solution with a concentration of 0.1 mg / mL. Take 500 μL of the 0.1 mg / mL solution and add it to 500 μL of DMEM medium to prepare a solution with a concentration of 0.05 mg / mL. Take 500 μL of the 0.05 mg / mL solution and add it to 500 μL of DMEM medium to prepare a solution with a concentration of 0.025 mg / mL. 2. Preparation of positive control and dosing formulations: Positive control: Chloroquine phosphate white or pale yellow powder, 5g. Source: Bidepharm Pharmaceuticals. Product number: BD263139-5g. Lot number: BNA684. Preparation of dosage formulation: Weigh out 2.24 mg of chloroquine phosphate and add it to 1.085 ml of DMEM, mix evenly to obtain a preliminary solution with a concentration of 4 mM. Take 100 μL of the mother solution and add it to 3900 μL of DMEM cell culture medium to prepare a solution with a concentration of 100 μM. 3. Test cells Name or code: HEK293 cell line stably expressing the ACE2 receptor. Seed source: Human fetal kidney cells. Tissue source: Normal kidney cells. Growth characteristics: Grows attached to the wall. Culture medium: DMEM medium 90%, FBS, 10%; 4. Testing recombinant SARS-CoV-2 Name: COVID-19 pseudovirus Virus: Guangzhou Packgene Biotech Lot number: LV-nCov1-2 Production: Using the pseudotyped lentivirus system vector, the pseudovirus is produced in a multiple plasmid co-transfected mammalian cell system, and infectious pseudovirus-like particles are produced by wrapping the pseudovirus capsid protein or envelope protein.Function: The recombinant COVID-19 pseudovirus can be used to detect the ability of test products to neutralize the entry of the pseudovirus, and must be operated in a biosafety level II laboratory. 5. Testing method: On D1, HEK293-ACE2 cells in the logarithmic growth phase were taken and the cell concentration was adjusted to 6.25 × 10 4 Adjust the concentration to cells / mL and add 5,000 cells / well / 80 μL to columns 2-7 and 9B-D of a 96-well plate, and add 80 μL of freshly prepared DMEM medium to column 8B-D. Incubate overnight at 37°C, 5% CO2. In D2, columns 2-6, add 10 μL of test products with concentrations of 50 μg / mL, 20 μg / mL, 10 μg / mL, 5 μg / mL and 2.5 μg / mL in order to the test product group in row BD, and add 10 μL of pseudovirus liquid at the same time; in column 7, add 10 μL of chloroquine phosphate to the positive control group in row BD, and add 10 μL of pseudovirus liquid at the same time; add 20 μL of medium to the blank control group (row BD, column 8), and add 10 μL of pseudovirus liquid and 10 μL of solvent control containing 0.25% DMSO to the negative control group (row BD, column 9). After culturing for 48 hours at 37℃ and 5% CO2, 40μL of 1× Reporter Lysis Buffer was added, and the mixture was left at -80℃ for 2 hours. After thawing again, the mixture was centrifuged at 4000r / min for 5 minutes. 20μL of the supernatant was taken and added to a 96-well white ELISA plate, and 100μL of Luciferase Assay Reagent was added to detect luciferase activity (RLU, a high RLU value indicates that a large amount of pseudovirus has infected and entered the cells). The plate layout is as follows:
[0074] [Table 2]
[0075] Results: After 48 hours of drug action, the RLU / RLUc value (the ratio of the fluorescence value of the experimental group to the average fluorescence intensity of the negative control group) of the positive control group was 0.05 ± 0.01, and the RLU / RLUc ratios of the test products from high to low concentrations (50 μg / mL, 20 μg / mL, 10 μg / mL, 5 μg / mL and 2.5 μg / mL) were 0.14 ± 0.04, 0.09 ± 0.03, 0.14 ± 0.04, 0.11 ± 0.01 and 0.17 ± 0.14, respectively. Compared with the negative control group, the RLU / RLUc ratios of each dose group of the test products and the positive control group were all significantly different (***P < 0.001, **P < 0.01). Figure 7 shows the inhibitory effect of Chinese herbal medicine extracts on COVID-19 pseudovirus-infected HEK293-ACE2 cells.
[0076] Test results: The results show that under the test conditions, when the concentration of the herbal extract is 2.5μg / mL-50μg / mL, the inhibition rate against COVID-19 pseudovirus reaches more than 50%, indicating that the herbal extract H157 has a very good inhibitory effect on the cell line HEK293 stably expressing the ACE2 receptor infected with COVID-19 pseudovirus.
[0077] Clinical therapeutic effects of the disclosed herbal medicine composition on cold and damp (i.e. viral pneumonia): The herbal medicine composition prepared in the present disclosure was adopted to conduct clinical trials. Target: Patients of Danjiangkou City Chinese Medicine Hospital Case 1: Mr. Chen, age 13. The pre-treatment imaging report showed multiple spotted shadows with increased density in the upper, middle and lower lobes of the right lung, some of which showed ground-glass opacity. The novel coronavirus test was negative. Diagnosis: right lung infectious virus, suspected viral pneumonia. After drug treatment with the herbal medicine composition of the present disclosure, imaging showed that the right lung infectious lesions were more absorbed than before drug use. Case 2: Mr. Wang, age 32. The pre-treatment imaging report showed a large number of spot-like and plate-like ground-glass-like shadows with increased density in the upper lobe of the right lung and the lower lobe of the left lung, some of which had actual changes in the lesions, among which air bronchograms were found, especially in the upper right. The new coronavirus test was negative. Diagnosis: There were infectious lesions in the upper lobe of the right lung and the lower lobe of the left lung, and viral pneumonia was initially considered. After drug treatment with the herbal medicine composition of the present disclosure, imaging diagnosis showed that the infectious lesions in the upper lobe of the right lung and the lower lobe of the left lung were absorbed and improved. Case 3: Mr. Xie, age 54. The pre-treatment imaging report showed an increased density spot-shaped shadow in the upper lobe of the right lung with a blurred edge, in which air bronchogram was observed. The novel coronavirus test was negative. Diagnosis: infectious lesion in the lower right lung. After drug treatment with the herbal medicine composition of the present disclosure, imaging diagnosis showed that the infectious lesion in the lower right lung was absorbed and improved compared to before the lesion. Re-examination is suggested. Case 4: A 17-year-old male, had a fever for 3 days, and was hospitalized. Symptoms: fever and chills, dry cough, sore throat, generalized pain, excessive sweating. Radiographic examination: right lower lung infection, possible viral pneumonia. Pathogen examination: the novel coronavirus nucleic acid test was negative. After drug treatment with the herbal medicine composition of the present disclosure, the fever disappeared, the sore throat disappeared, the cough was relieved, and the lung inflammation was absorbed. Case 5: A 41-year-old male with cough and phlegm for more than half a month, hospitalized. Symptoms: cough and phlegm. Radiographic examination: right upper lung infection, possible viral pneumonia. Pathogen examination: novel coronavirus nucleic acid test was negative. After 14 days of drug treatment with the disclosed herbal medicine composition, the cough and phlegm disappeared, the lung inflammation was absorbed, and the treatment effect was significant. Case 6: A 19-year-old male, with fever for 2 days with shortness of breath and dizziness, was hospitalized. Symptoms: fever, fatigue, dizziness, sore throat, cough. Radiographic examination: Infectious lesions were found in both lungs, and the possibility of viral pneumonia was high. Pathogen examination: The novel coronavirus nucleic acid test was negative. After three days of drug treatment with the disclosed herbal medicine composition, the fever disappeared, cough and phlegm were relieved, fatigue and loss of appetite were improved, and lung inflammation was absorbed, with a significant therapeutic effect. Case 7: A 30-year-old woman with cough and phlegm for 3 days, hospitalized. Symptoms: cough, phlegm and dry throat. Radiographic examination: right lower lung infection, possible viral pneumonia. Pathogen examination: novel coronavirus nucleic acid test was negative. After 4 days of drug treatment with the disclosed herbal medicine composition, cough and phlegm were relieved, dry throat was improved, and lung inflammation was absorbed, with significant therapeutic effects. Case 8: A 23-year-old male, with intermittent fever for 5 days, was hospitalized. Symptoms: fever, chills, cough, loss of appetite and lack of sleep. Radiography: left lower lobe infection, possible viral pneumonia. Pathogen test: novel coronavirus nucleic acid test was negative. After 7 days of drug treatment with the disclosed herbal medicine composition, fever and chills disappeared, cough improved, and inflammation in the lungs was absorbed, with a significant therapeutic effect. Case 9: A 31-year-old male, with fever for 15 days, chest tightness and pain for 7 days, hospitalized. Symptoms: headache, loss of appetite and fatigue. Radiographic examination: bilateral lung multiple infection, possible viral pneumonia. Pathogen examination: negative diagnosis by novel coronavirus nucleic acid test. After 6 days of drug treatment with the disclosed herbal medicine composition, the headache disappeared, fatigue and loss of appetite improved, lung inflammation was absorbed, and the treatment effect was significant.
[0078] The herbal composition of the present disclosure effectively alleviates or cures viral pneumonia, and after treatment, the inflammation was seen to be resolved on the chest radiograph of the patient, and lung function was restored. Finally, it should be noted that the above embodiments are used to explain the technical solutions of the present disclosure, and are not intended to limit the same. Although the present disclosure has been described in detail with reference to the above embodiments, those skilled in the art can make modifications to the technical solutions described in the above embodiments, or equivalent replacements of some or all of the technical features thereof, and can understand that such modifications or replacements do not deviate from the essence of the relevant technical solutions within the scope of the technical solutions of the embodiments of the present disclosure.
Claims
1. A step (1) of weighing out each raw material component in proportions by weight; (2) adding 15 parts by weight of water, infusing for 0.5 hours, and then boiling twice for 0.5 hours each time to extract the extract; combining the boiled liquids and filtering them to obtain an extract; Step (3) of concentrating the extract from step (2) under reduced pressure at 70°C to obtain a concentrate having a relative density of 1.10 to 1.20 g / mL measured at 50°C; Step (4) of taking the concentrated liquid of step (3) and spray-drying it to obtain a spray powder; and (5) taking the spray powder of step (4), adding dextrin and mixing it, and preparing granules by a wet method, the herbal medicine composition being prepared by the method comprising the steps of: For parts by weight: It is prepared from raw materials with a blend ratio of 250-400 parts by weight of dried tangerine peel, 100-200 parts by weight of Chinese atractylodes, 100-200 parts by weight of thick magnolia, 200-300 parts by weight of licorice, 200-300 parts by weight of Japanese iris, 200-300 parts by weight of Acorus gramineus, 250-330 parts by weight of jujube, and 100-200 parts by weight of ginger. A herbal medicine composition for treating novel coronavirus pneumonia.
2. Further comprising 500-700 parts by weight of an auxiliary material, said auxiliary material being a filler; The filler is dextrin, soluble starch or lactose. The herbal composition according to claim 1.
3. The herbal composition is an oral liquid, granule, powder, dripping pill, capsule, effervescent agent or tablet. The herbal composition according to claim 1 or 2.
4. Hesperidin thin layer chromatography including qualitative identification and content measurement of hesperidin, Further included is the thin layer chromatography qualitative identification of 6-gingerol, licorice and magnolol. A method for detecting the quality of the herbal medicine composition according to claim 1 or 2.
5. Thin layer chromatography qualitative identification: 2 g of the granule powder prepared from the herbal composition is dissolved by adding 25 ml of water, and is extracted twice with ethyl acetate, 20 ml each time, and the extracts are combined and evaporated to dryness. The residue is dissolved in 1 ml of methanol, which is used as the test solution. Separately, a hesperidin control is taken and saturated with methanol, which is used as the control solution. According to the thin layer chromatography test method, 2-5 μL of the test solution and 5 μL of the control solution are respectively sucked up on the same silica gel G thin layer plate, and developed with ethyl acetate-methanol-water in a volume ratio of 20:3:2 as the developing solvent, and then taken out and dried, sprayed with 5% aluminum trichloride ethanol solution, heated at 105° C. for 5-10 minutes, and inspected under an ultraviolet lamp at 365 nm. The same color spots appear in the chromatography of the test sample at the positions corresponding to the chromatography of the control drug. (1); Step (1) is used as the test sample solution, and 6-gingerol is used as the control sample, and ethyl acetate is added to prepare a solution containing 1 mg per mL, which is used as the control sample solution. According to the thin layer chromatography test method, 3-10 μL of the test sample solution and 1 μL of the control sample solution are sucked up and spotted on the same silica gel G thin layer plate, respectively, and developed with a volume ratio of 2:1:1 petroleum ether (60-90°C)-trichloromethane-ethyl acetate as the developing solvent, and then taken out and dried, and sprayed with 2% vanillin sulfuric acid solution, and heated at 105°C until spots are clearly visible, and the same color spots appear in the chromatography of the test sample at the positions corresponding to the chromatography of the control sample. Step (2); 3 g of the granules prepared from the herbal composition was taken, dissolved in 40 ml of water, and extracted with n-butanol three times, 20 ml each time, by shaking. The n-butanol solution was then combined, and the n-butanol solution was evaporated and dried at 20 ml each time. The residue was dissolved in 1 ml of methanol, which was used as the test sample solution. Separately, 1 g of the licorice control drug was taken, and 40 ml of water was added, refluxed for 1 hour, cooled, filtered, and extracted with n-butanol three times, 20 ml each time, by shaking. The n-butanol solution was then combined, and the n-butanol solution was evaporated and dried at 20 ml each time. The residue was dissolved in 1 ml of methanol, which was used as the test sample solution. (3) adding L to dissolve the solution and using it as a control solution; and by thin-layer chromatography test method, 2-5 μL of the test solution and 5 μL of the control drug solution are absorbed and spotted on a silica gel G thin-layer plate, respectively, and developed using ethyl acetate-formic acid-glacial acetic acid-water with a volume ratio of 15:1:1:2 as a developing solvent; removing and drying the plate; spraying with 10% sulfuric acid-ethanol solution; heating at 105°C until spots are clearly visible; and observing with an ultraviolet lamp at 365 nm; the same color fluorescent main spots appear in the position corresponding to the chromatography of the control drug in the chromatography of the test sample; 6 g of the granules prepared from the herbal composition are taken, ground finely, added with 40 ml of ethyl acetate, ultrasonicated for 30 minutes, filtered, the filtrate is evaporated to dryness, and the residue is dissolved by adding 1 ml of methanol, which is used as the test solution; separately, magnolol is taken, and a mixed solution containing 1 mg per ml of magnolol is prepared by adding methanol, which is used as the control solution; according to the thin layer chromatography test method, 10-15 μL of the test solution and 5 μL of the control solution are respectively spotted on the same silica gel G thin layer plate, and developed with toluene-ethyl acetate-methanol in a volume ratio of 18:3:1 as the developing solvent, and then taken out and dried, and sprayed with 1% vanillin sulfuric acid solution, and heated at 105° C. until spots are clearly visible, and the same color spots appear in the chromatography of the test sample at the positions corresponding to the chromatography of the control sample. (4) The method for detecting the quality of the herbal medicine composition according to claim 4.
6. The hesperidin content was measured using high performance liquid chromatography. Specifically, Octadecylsilane chemically bonded silica gel (ODS) was used as the packing material, and acetonitrile: 0.1% phosphoric acid solution = 19:81 volume ratio was used as the mobile phase. The detection wavelength was 283 nm, and the flow rate was 1.0 ml / min. The number of theoretical plates calculated based on the hesperidin peak is greater than or equal to 2000; Take an appropriate amount of hesperidin control sample, weigh it accurately, and add methanol to prepare a solution containing 15 μg per mL to prepare a control sample solution; Take the said herbal medicine composition, finely grind it, sieve it through a No. 5 sieve, take 0.3g, weigh it precisely, put it into a stoppered Erlenmeyer flask, add 50mL of 10% methanol precisely, weigh it, sonicate it for 30 minutes, cool it down and weigh it again, make up the weight lost by methanol, shake it well, filter it, and take the filtrate to prepare a test sample solution; The measurement method used was to precisely suck up 10 μL of the control solution and test solution, inject them into a liquid chromatograph, and measure them. Each gram of granules of this composition contains hesperidin (C 28 H 34 O 15 ) contains more than or equal to 2.325 mg A method for detecting the quality of the herbal medicine composition according to claim 4 or 5.
7. Use of the herbal medicine composition according to any one of claims 1 to 3, Use in the preparation of a drug for treating novel coronavirus pneumonia. Use of a herbal medicine composition comprising:
Citation Information
Patent Citations
Traditional Chinese medicinal composition for treating cold gastroenteropathy
CN101947304A
Traditional Chinese medicinal composition for treating cold as well as preparation method and application of traditional Chinese medicinal composition
CN104523929A
Traditional Chinese medicine composition for treating novel coronavirus pneumonia, preparation method, detection method and application of traditional Chinese medicine composition
CN111407877A
Peptic particle and preparing method thereof
CN1456292A
